Open AccessUpdated 2020 guidelines for diagnosis and treatment of invasive aspergillosis in children with hematologic malignancy
Author(s) -
G.G. Solopova,
Alexei Maschan,
Galiovichkova
Publication year - 2020
Publication title -
voprosy gematologii/onkologii i immunopatologii v pediatrii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.108
H-Index - 3
eISSN - 2414-9314
pISSN - 1726-1708
DOI - 10.24287/1726-1708-2020-19-1-158-166
Subject(s) - medicine , hematologic malignancy , aspergillosis , intensive care medicine , malignancy , antifungal , hematologic neoplasms , myeloid leukemia , hematological malignancy , acute leukemia , pediatrics , leukemia , transplantation , immunology , dermatology
Invasive aspergillosis (IA) is a major cause of morbidity in immunocompromised children. Patients with acute myeloid leukemia, relapsed acute luekemia and stem cells recipients are at high-risk for IA. Despite improving of diagnosis, prevention and treatment of IA mortality remains high. The main factors for favorable outcome of IA are early diagnosis and prompt appropriate treatment. Currently, few different international guidelines for IA have been developed but there are no Russian recommendations. An additional problem typical for Russia is poor level of microbiological diagnostic leading to underestimated frequency of IA or non-appropriate usage of antifungal drugs. This article presents an algorithm for diagnosis and treatment of IA in immunocompromised patient taking into account the characteristics of children with hematologic malignancy.